Radiation safety management for stereotactic body radiation therapy incidentally concurrent with Pluvicto® (Lu‐177) therapy ‐ a case report
Abstract
Abstract A patient with castration‐resistant prostate cancer (CRPC) was referred to our clinic seeking palliative management of a painful metastasis in the left pelvis. At the time of referral, the patient was receiving [177Lu]Lu‐PSMA 617 (Pluvicto®) therapy at an outside institution, with the next scheduled administration approaching within days. As the patient's next Pluvicto® cycle could coincide with the planned SBRT, the radiation oncologist consulted with the medical health physics team to evaluate potential radiation safety concerns and to determine an appropriate treatment timeline. This case report details the radiation safety considerations, dose estimations, and the measured dose rate readings on the patient to balance the optimal patient care and to minimize staff exposure.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.